Cargando…

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients

OBJECTIVE: To evaluate serum cytokine profiles for their utility to determine the heterogeneous responses to interferon (IFN)–β treatment in patients with multiple sclerosis (MS). METHODS: Patients with relapsing-remitting MS (RRMS) or clinically isolated syndrome receiving de novo IFN-β treatment w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hegen, Harald, Adrianto, Indra, Lessard, Christopher J., Millonig, Alban, Bertolotto, Antonio, Comabella, Manuel, Giovannoni, Gavin, Guger, Michael, Hoelzl, Martina, Khalil, Michael, Fazekas, Franz, Killestein, Joep, Lindberg, Raija L.P., Malucchi, Simona, Mehling, Matthias, Montalban, Xavier, Rudzki, Dagmar, Schautzer, Franz, Sellebjerg, Finn, Sorensen, Per Soelberg, Deisenhammer, Florian, Steinman, Lawrence, Axtell, Robert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747480/
https://www.ncbi.nlm.nih.gov/pubmed/26894205
http://dx.doi.org/10.1212/NXI.0000000000000202
_version_ 1782414985409855488
author Hegen, Harald
Adrianto, Indra
Lessard, Christopher J.
Millonig, Alban
Bertolotto, Antonio
Comabella, Manuel
Giovannoni, Gavin
Guger, Michael
Hoelzl, Martina
Khalil, Michael
Fazekas, Franz
Killestein, Joep
Lindberg, Raija L.P.
Malucchi, Simona
Mehling, Matthias
Montalban, Xavier
Rudzki, Dagmar
Schautzer, Franz
Sellebjerg, Finn
Sorensen, Per Soelberg
Deisenhammer, Florian
Steinman, Lawrence
Axtell, Robert C.
author_facet Hegen, Harald
Adrianto, Indra
Lessard, Christopher J.
Millonig, Alban
Bertolotto, Antonio
Comabella, Manuel
Giovannoni, Gavin
Guger, Michael
Hoelzl, Martina
Khalil, Michael
Fazekas, Franz
Killestein, Joep
Lindberg, Raija L.P.
Malucchi, Simona
Mehling, Matthias
Montalban, Xavier
Rudzki, Dagmar
Schautzer, Franz
Sellebjerg, Finn
Sorensen, Per Soelberg
Deisenhammer, Florian
Steinman, Lawrence
Axtell, Robert C.
author_sort Hegen, Harald
collection PubMed
description OBJECTIVE: To evaluate serum cytokine profiles for their utility to determine the heterogeneous responses to interferon (IFN)–β treatment in patients with multiple sclerosis (MS). METHODS: Patients with relapsing-remitting MS (RRMS) or clinically isolated syndrome receiving de novo IFN-β treatment were included in this prospective, observational study. Number of relapses and changes in disability were assessed 2 years prior to and 2 years after initiation of treatment. Sera were collected at baseline and after 3 months on therapy. Cytokine levels in sera were assessed by Luminex multiplex assays. Baseline cytokine profiles were grouped by hierarchical clustering analysis. Demographic features, changes in cytokines, and clinical outcome were then assessed in the clustered patient groups. RESULTS: A total of 157 patients were included in the study and clustered into 6 distinct subsets by baseline cytokine profiles. These subsets differed significantly in their clinical and biological response to IFN-β therapy. Two subsets were associated with patients who responded poorly to therapy. Two other subsets, associated with a good response to therapy, showed a significant reduction in relapse rates and no worsening of disability. Each subset also had differential changes in cytokine levels after 3 months of IFN-β treatment. CONCLUSIONS: There is heterogeneity in the immunologic pathways of the RRMS population, which correlates with IFN-β response.
format Online
Article
Text
id pubmed-4747480
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-47474802016-02-18 Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients Hegen, Harald Adrianto, Indra Lessard, Christopher J. Millonig, Alban Bertolotto, Antonio Comabella, Manuel Giovannoni, Gavin Guger, Michael Hoelzl, Martina Khalil, Michael Fazekas, Franz Killestein, Joep Lindberg, Raija L.P. Malucchi, Simona Mehling, Matthias Montalban, Xavier Rudzki, Dagmar Schautzer, Franz Sellebjerg, Finn Sorensen, Per Soelberg Deisenhammer, Florian Steinman, Lawrence Axtell, Robert C. Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: To evaluate serum cytokine profiles for their utility to determine the heterogeneous responses to interferon (IFN)–β treatment in patients with multiple sclerosis (MS). METHODS: Patients with relapsing-remitting MS (RRMS) or clinically isolated syndrome receiving de novo IFN-β treatment were included in this prospective, observational study. Number of relapses and changes in disability were assessed 2 years prior to and 2 years after initiation of treatment. Sera were collected at baseline and after 3 months on therapy. Cytokine levels in sera were assessed by Luminex multiplex assays. Baseline cytokine profiles were grouped by hierarchical clustering analysis. Demographic features, changes in cytokines, and clinical outcome were then assessed in the clustered patient groups. RESULTS: A total of 157 patients were included in the study and clustered into 6 distinct subsets by baseline cytokine profiles. These subsets differed significantly in their clinical and biological response to IFN-β therapy. Two subsets were associated with patients who responded poorly to therapy. Two other subsets, associated with a good response to therapy, showed a significant reduction in relapse rates and no worsening of disability. Each subset also had differential changes in cytokine levels after 3 months of IFN-β treatment. CONCLUSIONS: There is heterogeneity in the immunologic pathways of the RRMS population, which correlates with IFN-β response. Lippincott Williams & Wilkins 2016-01-27 /pmc/articles/PMC4747480/ /pubmed/26894205 http://dx.doi.org/10.1212/NXI.0000000000000202 Text en © 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Article
Hegen, Harald
Adrianto, Indra
Lessard, Christopher J.
Millonig, Alban
Bertolotto, Antonio
Comabella, Manuel
Giovannoni, Gavin
Guger, Michael
Hoelzl, Martina
Khalil, Michael
Fazekas, Franz
Killestein, Joep
Lindberg, Raija L.P.
Malucchi, Simona
Mehling, Matthias
Montalban, Xavier
Rudzki, Dagmar
Schautzer, Franz
Sellebjerg, Finn
Sorensen, Per Soelberg
Deisenhammer, Florian
Steinman, Lawrence
Axtell, Robert C.
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
title Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
title_full Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
title_fullStr Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
title_full_unstemmed Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
title_short Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
title_sort cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747480/
https://www.ncbi.nlm.nih.gov/pubmed/26894205
http://dx.doi.org/10.1212/NXI.0000000000000202
work_keys_str_mv AT hegenharald cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT adriantoindra cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT lessardchristopherj cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT millonigalban cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT bertolottoantonio cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT comabellamanuel cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT giovannonigavin cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT gugermichael cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT hoelzlmartina cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT khalilmichael cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT fazekasfranz cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT killesteinjoep cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT lindbergraijalp cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT malucchisimona cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT mehlingmatthias cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT montalbanxavier cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT rudzkidagmar cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT schautzerfranz cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT sellebjergfinn cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT sorensenpersoelberg cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT deisenhammerflorian cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT steinmanlawrence cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients
AT axtellrobertc cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients